Faropenem


Generic Medicine Info
Indications and Dosage
Oral
Respiratory tract infections, Uncomplicated skin and skin structure infections
Adult: As faropenem medoxomil: 300 mg bid for 7-10 days.
Contraindications
History of hypersensitivity to faropenem and other penems, anaphylactic reaction to β-lactams.
Adverse Reactions
Diarrhoea, nausea, vomiting and abdominal pain.
Food Interaction
Slightly delays time to peak plasma concentration w/ food.
Action
Description:
Mechanism of Action: Faropenem is a penem antimicrobial and has bactericidal activity against a variety of gm-ve, gm+ve and anaerobic bacteria.
Pharmacokinetics:
Absorption: Food slightly delays time to peak plasma concentration. Time to peak plasma concentration: W/in 1-2 hr.
Distribution: Plasma protein binding: 89-90%.
Metabolism: Metabolised by renal dihydropeptidase I to 2 inactive metabolites.
Excretion: Half-life: Approx 1 hr.
Chemical Structure

Chemical Structure Image
Faropenem

Source: National Center for Biotechnology Information. PubChem Database. Faropenem, CID=65894, https://pubchem.ncbi.nlm.nih.gov/compound/Faropenem (accessed on Jan. 20, 2020)

MIMS Class
Other Beta-Lactams
References
Buckingham R (ed). Faropenem Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 22/09/2014.

Wickersham RM. Faropenem Medoxomil. Facts and Comparisons [online]. St. Louis, MO. Wolters Kluwer Clinical Drug Information, Inc. https://www.wolterskluwercdi.com/facts-comparisons-online/. Accessed 22/09/2014.

Disclaimer: This information is independently developed by MIMS based on Faropenem from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in